Results 1 to 10 of about 636,170 (221)
Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
Molecules, 2021 Bruton’s tyrosine kinase (BTK) plays a crucial role in B-cell receptor and Fc receptor signaling pathways. BTK is also involved in the regulation of Toll-like receptors and chemokine receptors.
Datong Zhang, He Gong, Fancui Meng
doaj +4 more sources
BTK inhibitors: past, present, and future [PDF]
Trends in Pharmacological SciencesBruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment landscape for B cell lymphomas such as chronic lymphocytic leukemia (CLL). The first-in-class BTK inhibitor ibrutinib has recently been succeeded by covalent BTK inhibitors that are safer but still face challenges of resistance mutations.
Skye Montoya, Justin Taylor
exaly +5 more sources
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia [PDF]
eLifeInhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders, and multiple sclerosis. Since the approval of the first BTK inhibitor
Raji E Joseph +7 more
doaj +3 more sources
Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting [PDF]
Journal of Hematology & OncologyAlthough covalent and non-covalent Bruton tyrosine kinase inhibitors (BTKi) have extended clinical benefit to relapsed/refractory (R/R) and BTKi-resistant chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), there remains an unmet need for ...
Pritika Sharma, Heng Jiang, Delong Liu
doaj +2 more sources
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
Journal of Hematology & Oncology, 2021 B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies. Activation of BCR signaling promotes the survival and proliferation of malignant B cells.
Danling Gu +4 more
doaj +1 more source
Molecules, 2023 Bruton tyrosine kinase (BTK) is an essential enzyme in the signaling pathway of the B-cell receptor (BCR) and is vital for the growth and activation of B-cells.
Qi Zhang +3 more
doaj +1 more source
Медицинская иммунология, 2023 Bruton's tyrosine kinase (BTK) inhibitors represent a class of drugs that have demonstrated their efficacy and safety in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphomas who were considered refractory to any previously used type of ...
Yu. S. Torshina +4 more
doaj +1 more source
Biomarker Research, 2022 The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and manageable toxicities in ...
Jing Zhang +3 more
doaj +1 more source
Experimental Hematology & Oncology, 2023 Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good clinical ...
Yuqin Song +18 more
doaj +1 more source
Heliyon, 2023 Bruton's tyrosine kinase (BTK) is a protein involved in B-cell-receptor signaling and B-cell proliferation. The pathophysiology of several autoimmune diseases, such as pemphigus disorder, relies on the BTK signaling pathway.
Yekta Ghane +4 more
doaj +1 more source